14 January 2019: Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Niklas Sandler as Chief Technology Officer. The role will combine significant pharmaceutical R&D knowledge with commercial expertise to develop the technological resources required for Nanoform’s growth ambitions.
Dr Sandler will succeed the previous acting Chief Technology Officer, Dr Jouko Yliruusi, who together with CEO Dr Edward Hæggström, has led the development of Nanoform’s proprietary particle engineering technology during the last 10 years. Following his recent retirement from the University of Helsinki, Dr Yliruusi, will now be progressing to a Senior Advisory role within Nanoform.
Dr Sandler has extensive experience in both industry and academia, particularly in pharmaceutical product development and material science. His most recent role was as Vice Rector responsible for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University, Finland. His work within industry at AstraZeneca Pharmaceuticals, won him an award for technological innovation. Dr Sandler has published over 100 papers in major international journals and is an acting referee on multiple global pharmaceutical journals, including the Journal of Pharmaceutical Sciences.
The employment of a new Chief Technology Officer follows a recent expansion in facilities with the construction of a 1200m2 GMP-compliant plant and the appointment of both Christian Jones as Chief Commercial Officer and Gonçalo Rebelo de Andrade as Chief of Business Operations. The combination of this increased capacity and strengthened commercial organisation will ensure that Nanoform delivers exceptional solutions to address its partners’ complex product development challenges.
Edward Hæggström, CEO of Nanoform said: “I am delighted to welcome Niklas Sandler to Nanoform. His exceptional experience in pharmaceutical technology and product development will be a huge asset to the company and allow us to set ambitious goals to enhance our commercial offering.”
Niklas Sandler said: “I am excited to be joining Nanoform’s dynamic environment and a team that is passionate about transforming the pharmaceutical industry. My career has focused on enhancing the commercial application of research, and Nanoform’s use of cutting-edge nanonization technology exemplifies how innovations are transforming the sector.”
Jouko Yliruusi added:“It has been a great journey developing the CESSᵀᴹ technology and watching Nanoform grow into the company that it is today. I look forward to continuing to support the business going forward. I am delighted that Niklas, whom I’ve worked with for a long time, will be taking the reins and leading the R&D organisation and commercialisation of the technology in a GMP environment.”
Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ ) technology produces nanonized ‘designed-for-purpose’ API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information please visit https://www.nanoform.fi/